• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • TheStreet Smarts
  1. Home
  2. / Investing
  3. / Healthcare

Sellers Are Dominating the Price Action in Biogen

Shoppers may want to wait until after the holidays for a bargain on BIIB.
By BRUCE KAMICH
Dec 13, 2016 | 09:09 AM EST
Stocks quotes in this article: BIIB

Biogen  (BIIB) is trading in a rare world of the really high-priced stocks. I don't know how many stocks are trading in the $300s, but I would guess it is a short list. Being a high-priced stock does not mean it is overpriced or overvalued, it just means that buying a round lot gives you a little pause. If you have been considering buying BIIB in the past few months, you may want to hold off a little longer as it looks like sellers are still dominating the price action.

In this daily chart of BIIB, below, we can see two different "phases" for the trading of BIIB in the past year. The first phase is from December to June, where prices traded sideways to lower. The 200-day moving average line is declining in that time frame and the 50-day average is mostly flat.

The On-Balance-Volume (OBV) line rises gradually from January to early June. The second phase of trading, after a sharp advance in July, is from August until now. Prices move sideways with a ceiling around $330 and dips to $280 or so finding buying interest.

Digging deeper, we see that for much of this period the 50-day moving average line is declining, and while the 200-day average is rising, it has been tested in November and December. So far, the 200-day line is acting as support, but the OBV line has worked lower in the past four weeks -- suggesting that sellers have become more aggressive. In the bottom panel is the 12-day momentum study, and it is not showing a bullish divergence.

In this three-year weekly chart of BIIB, above, we can see that BIIB has been testing the rising, 40-week moving average line. The next two panels of this chart are bearish. The weekly OBV line has been declining for two months, and suggests some aggressive selling. The trend-following Moving Average Convergence Divergence (MACD) oscillator is in a bearish mode and pointed down towards the zero line. While not yet at an outright sell signal, the MACD oscillator looks like it is headed in that direction.

In this Point and Figure chart of BIIB, above, we don't want to focus on potential price targets, but rather what prices might tip the chart up or down. BIIB is in a down column of Os right now. A rally to $336.60 would be needed to make an upside breakout. On the downside, a move to $271 could weaken the chart further.

Bottom line: There are enough technical clues to defer buying BIIB at this time. Shoppers may want to wait until after the holidays to see if they can get a better bargain.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are restricted from owning individual securities.

TAGS: Investing | U.S. Equity | Healthcare | Technology | Markets | Stocks

More from Healthcare

There Are Market Bright Spots, but I View the July Rally as a Head Fake

Bret Jensen
Aug 3, 2022 10:30 AM EDT

It's hard to see stock valuations rising when inflation remains high and the economy appears headed for a recession if it isn't in one already.

A Recession Appears Inevitable, but There Are Still Places to Invest

Bret Jensen
Jul 27, 2022 10:30 AM EDT

A few homebuilders and healthcare stocks seem likely to hold up better than most of the market in a recession.

Change Healthcare Continues to Knock on a Breakout Level

Bruce Kamich
Jul 25, 2022 11:25 AM EDT

The CHNG chart is at an interesting juncture.

The Healing Process Begins for Cano Health

Bruce Kamich
Jul 21, 2022 1:30 PM EDT

Here's how to approach CANO as the shares have made a bottom formation.

With HCA Healthcare, I'm Getting Healthy Indications

Bruce Kamich
Jul 21, 2022 9:20 AM EDT

The healthcare provider is set to report earnings Friday.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 09:24 AM EDT PETER TCHIR

    Jobs Report Reaction: Incredibly Strong, But Questions to Ask

    An incredibly strong July jobs report. Not only d...
  • 08:54 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    The Secret to Dealing With FOMO
  • 03:51 PM EDT REAL MONEY

    AMD Second-Quarter Earnings Live Blog

    Real Money's Eric Jhonsa covers 's second-quarte...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login